Details of the Drug

General Information of Drug (ID: DM57J20)

Drug Name
AZD0186
Indication
Disease Entry ICD 11 Status REF
Type 2 diabetes 5A11 Phase 1 [1]
Drug Type
Small molecule
Cross-matching ID
TTD ID
DPFY92

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucagon-like peptide 1 receptor (GLP1R) TTVIMDE GLP1R_HUMAN Agonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 05 Endocrine, nutritional or metabolic disease
Disease Class ICD-11: 5A11 Type 2 diabetes mellitus
The Studied Tissue Liver tissue
The Studied Disease Type 2 diabetes [ICD-11:5A11]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glucagon-like peptide 1 receptor (GLP1R) DTT GLP1R 1.25E-01 0.17 1.26
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05694741) A Phase 1 Randomized, Single-blind, Placebo-controlled, First-in-Human and Sequential Group Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186 Following Single Ascending Doses Via Oral Administration. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of AstraZeneca